Table 2 Factors associated with progression-free survival (PFS) by univariate and multivariate analysis
PFS | univariate analysis | multivariate analysis | ||
|---|---|---|---|---|
Variables | HR [95%CI] | p | HR [95%CI] | p |
11q deletion (n = 153) | ||||
No (ref) | 1.00 | 1.00 | ||
Yes | 2.19 [1.35; 3.56] | 0.0012 | 1.74 [0.94; 3.21] | 0.076 |
IGHV mutation status (n = 131) | ||||
Mutated (ref) | 1.00 | 1.00 | ||
Unmutated | 2.55 [1.42; 4.59] | 0.0012 | 2.03 [1.02; 4.04] | 0.043 |
EOT MRDa (n = 131) | ||||
Low (ref) | 1.00 | 1.00 | ||
Intermediate | 2.64 [1.55; 4.50] | 2.43 [1.39; 4.27] | 0.002 | |
High | 6.95 [3.24; 14.92] | < 0.0001 | 4.56 [1.76;11.79] | 0.002 |
EOT CD4a (/mm3, n = 132) | ||||
≤ 200 (ref) | 1.00 | 1.00 | ||
> 200 | 2.28 [1.35; 3.86] | 0.0016 | 3.30 [1.79; 6.06] | < 0.001 |
EOT NKa (/mm3, n = 109) | ||||
≤ 100 (ref) | 1.00 | – | – | |
> 100 | 1.03 [0.60; 1.78] | 0.9101 | ||
EOT CD8a (/mm3, n = 132) | ||||
≤ 150 (ref) | 1.00 | – | – | |
> 150 | 1.02 [0.62; 1.66] | 0.9418 | ||
EOT monocytesa (/mm3, n = 114) | ||||
≤ 400 (ref) | 1.00 | – | – | |
> 400 | 1.30 [0.77; 2.19] | 0.3257 | ||